BONUSCAP-ZERTIFIKAT - NOVO-NORDISK B | Real-time BOERSE MUENCHEN 15:45:17 2024-06-24 EDT | ||
| 884.8 EUR | +0.09% |
|
| Current month | +0.23% | ||
| 1 month | +0.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-24 | 884.8 | +0.09% |
| 24-06-21 | 884 | +0.00% |
| 24-06-20 | 883.9 | -0.03% |
| 24-06-19 | 884.2 | +0.07% |
| 24-06-18 | 883.6 | +0.03% |
Real-time BOERSE MUENCHEN
Last update June 24, 2024 at 03:45 pm
More quotesStatic data
| Product type | Bonus- and Part-Guarantee-Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD0CH6 |
| ISIN | DE000HD0CH60 |
| Date issued | 2023-11-01 |
| Strike | 900 kr |
| Maturity | 2024-12-20 (179 Days) |
| Parity | 1 : 1 |
| Emission price | 773.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 885.4 € |
|---|---|
| Lowest since issue | 755.4 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
988.4
DKK
Average target price
934.3
DKK
Spread / Average Target
-5.48%
- Stock Market
- Certificates
- Certificat
